Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ezogabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ2 known ✓ | O43526 | 8/20 | 1.00 |
| ▸ | KCNQ3 known ✓ | O43525 | 6/20 | 1.00 |
| ▸ | KCNQ4 known ✓ | P56696 | 6/20 | 1.00 |
| ▸ | KCNQ5 known ✓ | Q9NR82 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.65 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.65 |
| ▸ | ESR1 | P03372 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | HTR1A | P08908 | 1/20 | 0.65 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | CASP1 | P29466 | 1/20 | 0.65 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ezogabine SCHEMBL20835 | 1.00 | KCNQ2 (1.00) | KCNQ2KCNQ3KCNQ4KCNQ5CYP1A2 | |
| Ezogabine SCHEMBL4054750 | 1.00 | KCNQ2 (1.00) | KCNQ2KCNQ3KCNQ4KCNQ5CYP1A2 | |
| Ezogabine SCHEMBL15357224 | 1.00 | KCNQ2 (1.00) | KCNQ2KCNQ3KCNQ4KCNQ5CYP1A2 | |
| Ezogabine SCHEMBL154715 | 0.99 | KCNQ2 (0.98) | KCNQ2KCNQ3KCNQ4KCNQ5CYP1A2 | |
| Ezogabine SCHEMBL155918 | 0.99 | KCNQ2 (0.98) | KCNQ2KCNQ3KCNQ4KCNQ5CYP1A2 | |
| Ezogabine SCHEMBL15539530 | 0.97 | KCNQ2 (0.94) | KCNQ2KCNQ3KCNQ4KCNQ5CYP1A2 | |
| SCHEMBL3102203 | 0.93 | KCNQ2 (0.87) | KCNQ2KCNQ3KCNQ4KCNQ5CYP1A2 | |
| SCHEMBL30824720 | 0.93 | KCNQ2 (0.87) | KCNQ2KCNQ3KCNQ4KCNQ5CYP1A2 | |
| Ezogabine SCHEMBL28471969 | 0.93 | KCNQ2 (0.86) | KCNQ2KCNQ3KCNQ4KCNQ5CYP1A2 | |
| SCHEMBL29754400 | 0.91 | KCNQ2 (0.83) | KCNQ2KCNQ3KCNQ4KCNQ5CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 633 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026099804-A2 | METHOD | SANIA TX LTD (GB) | 2026-05-15 | — | — | WO | claimed |
| WO-2026099781-A1 | METHOD | SANIA TX LTD (GB) | 2026-05-15 | — | — | WO | claimed |
| US-20260076971-A1 | METHODS OF TREATING EPILEPSY AND REDUCING THE INCIDENCE OF SEIZURES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2026-03-19 | — | — | US | claimed |
| EP-4709865-A1 | METHOD | Sania TX Ltd (GB) | 2026-03-18 | — | — | EP | claimed |
| EP-4695613-A2 | METHODS OF MODIFYING NEURONS IN VIVO TO TREAT AND/OR PREVENT AMYOTROPHIC LATERAL SCLEROSIS (ALS) | Yale University (US) | 2026-02-18 | — | — | EP | claimed |
| US-20260027337-A1 | TRANSDERMAL DRUG DELIVERY DEVICES AND METHODS | MORNINGSIDE VENTURE INVESTMENTS LTD (MC) | 2026-01-29 | — | — | US | claimed |
| EP-4680203-A1 | COMPOSITIONS FOR SUSTAINED RELEASE OF POORLY SOLUBLE ACTIVE INGREDIENTS | Prolevi Bio AB (SE) | 2026-01-21 | — | — | EP | claimed |
| US-12515030-B2 | Transdermal drug delivery devices and methods | MORNINGSIDE VENTURE INVESTMENTS LIMITED (MC) | 2026-01-06 | — | — | US | claimed |
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | UNIV COLUMBIA (US) | 2025-12-18 | — | — | US | claimed |
| US-12498384-B2 | Biomarkers and methods for evaluation and treatment of epileptic vs non-epileptic seizures / no seizures / psychogenic non-epileptic seizures | COGNIZANCE BIOMARKERS, INC. (US) | 2025-12-16 | — | — | US | claimed |
| WO-2022266112-A1 | ALSTONINE DERIVATIVES AND SALTS THEREOF | NAPO PHARMACEUTICALS, INC. (US) | 2022-12-22 | — | — | WO | claimed |
| US-20220380383-A1 | NEUROPROTECTIVE PDI MODULATING SMALL MOLECULES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK | 2022-12-01 | — | — | US | claimed |
| WO-2022251306-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING FERROPTOSIS AND TREATING EXCITOTOXIC DISORDERS | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2022-12-01 | — | — | WO | claimed |
| CN-114760990-A | Pediatric immediate release formulation of the potassium channel opener Ezogatabine | 泽农医药公司 | 2022-07-15 | — | — | CN | claimed |
| US-20220211658-A1 | METHODS FOR TREATING DISORDERS ASSOCIATED WITH SLEEP SPINDLE DEFICITS | THE BROAD INSTITUTE, INC. (US) | 2022-07-07 | — | — | US | claimed |
| US-20220178948-A1 | BIOMARKERS AND METHODS FOR DETECTION OF SEIZURES AND EPILEPSY | EVOGEN, INC. (US) | 2022-06-09 | — | — | US | claimed |
| EP-3261640-B1 | 5HT AGONISTS FOR TREATING EPILEPSY DISORDERS | UNIV CALIFORNIA (US) | 2022-04-06 | — | — | EP | claimed |
| US-11285306-B2 | Transdermal drug delivery devices and methods | MORNINGSIDE VENTURE INVESTMENTS LIMITED (US) | 2022-03-29 | — | — | US | claimed |
| US-11285161-B2 | Method and composition for treating mental disorder and pain associated with nerve damage | CITY UNIVERSITY OF HONG KONG (HK) | 2022-03-29 | — | — | US | claimed |
| US-20220034911-A1 | METHOD OF MITIGATION OF DEATH FROM EPILEPTIC SEIZURES | VEGA JOSE (US) | 2022-02-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11285161-B2 | Method and composition for treating mental disorder and pain associated with nerve damage | NTSR2, CCKAR, CCKBR | KCNQ2 758/4885KCNQ3 733/4885KCNQ4 1146/4885 |
| US-20260027337-A1 | TRANSDERMAL DRUG DELIVERY DEVICES AND METHODS | CAMK1, CAMK2B, CAMK4 | KCNQ2 1595/4885KCNQ3 1594/4885KCNQ4 1628/4885 |
| US-20250382291-A1 | SUBSTITUTED PYRROLO[2,3-b]PYRIDINES FOR SUPPRESSING TOXIC ENDOPLASMIC RETICULUM STRESS | HSPA5, ATP2A1, DNAJC10 | KCNQ2 3932/4885KCNQ3 4056/4885KCNQ4 4202/4885 |
| US-20260076971-A1 | METHODS OF TREATING EPILEPSY AND REDUCING THE INCIDENCE OF SEIZURES | JAK1, JAK3, STAT1 | KCNQ2 215/4885KCNQ3 201/4885KCNQ4 179/4885 |
| US-20220380383-A1 | NEUROPROTECTIVE PDI MODULATING SMALL MOLECULES AND METHODS OF USE THEREOF | NLN, PDIA5, PRNP | KCNQ2 3206/4885KCNQ3 3435/4885KCNQ4 3665/4885 |
| US-20220211658-A1 | METHODS FOR TREATING DISORDERS ASSOCIATED WITH SLEEP SPINDLE DEFICITS | HCRTR2, GRIN2A, GRM2 | KCNQ2 301/4885KCNQ3 483/4885KCNQ4 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.